StockNews.com Begins Coverage on Calithera Biosciences (NASDAQ:CALA)

Posted by Defense World Staff on Apr 12th, 2023

Equities researchers at StockNews.com assumed coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Calithera Biosciences Price Performance

NASDAQ CALA opened at $0.05 on Wednesday. The firm’s fifty day moving average price is $0.08 and its 200 day moving average price is $1.40. The company has a market capitalization of $253,240.00, a price-to-earnings ratio of 0.00 and a beta of 1.20. Calithera Biosciences has a 12 month low of $0.04 and a 12 month high of $7.95.

Insiders Place Their Bets

In other Calithera Biosciences news, Director Deepika Pakianathan sold 121,333 shares of Calithera Biosciences stock in a transaction dated Friday, January 27th. The shares were sold at an average price of $0.39, for a total transaction of $47,319.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Calithera Biosciences

A number of institutional investors have recently bought and sold shares of CALA. Affinity Asset Advisors LLC acquired a new stake in Calithera Biosciences in the first quarter valued at $404,000. Renaissance Technologies LLC increased its stake in Calithera Biosciences by 36.5% during the first quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company’s stock valued at $749,000 after purchasing an additional 496,100 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Calithera Biosciences by 143.2% during the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 72,865 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in Calithera Biosciences during the first quarter valued at $404,000. Finally, TSP Capital Management Group LLC increased its stake in Calithera Biosciences by 18.0% during the third quarter. TSP Capital Management Group LLC now owns 62,900 shares of the biotechnology company’s stock valued at $185,000 after purchasing an additional 9,605 shares during the last quarter. 33.73% of the stock is currently owned by hedge funds and other institutional investors.

Calithera Biosciences Company Profile

(Get Rating)

Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.